EP0649464A1 - Transfection of vertebrate cells e.g. by homologous recombination. - Google Patents
Transfection of vertebrate cells e.g. by homologous recombination.Info
- Publication number
- EP0649464A1 EP0649464A1 EP92924367A EP92924367A EP0649464A1 EP 0649464 A1 EP0649464 A1 EP 0649464A1 EP 92924367 A EP92924367 A EP 92924367A EP 92924367 A EP92924367 A EP 92924367A EP 0649464 A1 EP0649464 A1 EP 0649464A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- product
- transfected
- primary
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01204619A EP1221477A3 (en) | 1991-11-05 | 1992-11-05 | Transfection of vertebrate cells e.g. by homologous recombination |
EP96202037A EP0750044B1 (en) | 1991-11-05 | 1992-11-05 | DNA constructs and transfection of cells therewith for homologous recombination |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78784091A | 1991-11-05 | 1991-11-05 | |
US78918891A | 1991-11-05 | 1991-11-05 | |
US787840 | 1991-11-05 | ||
US789188 | 1991-11-05 | ||
US91153392A | 1992-07-10 | 1992-07-10 | |
US911533 | 1992-07-10 | ||
PCT/US1992/009627 WO1993009222A2 (en) | 1991-11-05 | 1992-11-05 | Transfection of vertebrate cells e.g. by homologous recombination |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96202037A Division EP0750044B1 (en) | 1991-11-05 | 1992-11-05 | DNA constructs and transfection of cells therewith for homologous recombination |
EP96202037.6 Division-Into | 1996-07-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0649464A1 true EP0649464A1 (en) | 1995-04-26 |
EP0649464B1 EP0649464B1 (en) | 1997-07-23 |
Family
ID=27419842
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92924367A Revoked EP0649464B1 (en) | 1991-11-05 | 1992-11-05 | Transfection of vertebrate cells e.g. by homologous recombination |
EP96202037A Expired - Lifetime EP0750044B1 (en) | 1991-11-05 | 1992-11-05 | DNA constructs and transfection of cells therewith for homologous recombination |
EP01204619A Withdrawn EP1221477A3 (en) | 1991-11-05 | 1992-11-05 | Transfection of vertebrate cells e.g. by homologous recombination |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96202037A Expired - Lifetime EP0750044B1 (en) | 1991-11-05 | 1992-11-05 | DNA constructs and transfection of cells therewith for homologous recombination |
EP01204619A Withdrawn EP1221477A3 (en) | 1991-11-05 | 1992-11-05 | Transfection of vertebrate cells e.g. by homologous recombination |
Country Status (19)
Country | Link |
---|---|
US (7) | US5994127A (en) |
EP (3) | EP0649464B1 (en) |
JP (3) | JP3564126B2 (en) |
KR (1) | KR100339316B1 (en) |
AT (2) | ATE155810T1 (en) |
AU (1) | AU669499B2 (en) |
CA (1) | CA2122991A1 (en) |
DE (2) | DE69221168T2 (en) |
DK (2) | DK0750044T3 (en) |
ES (2) | ES2181841T3 (en) |
GR (1) | GR3025054T3 (en) |
HK (1) | HK1014033A1 (en) |
IL (1) | IL103649A0 (en) |
MX (1) | MX9206376A (en) |
MY (1) | MY119132A (en) |
NZ (1) | NZ245015A (en) |
PT (1) | PT101031B (en) |
SG (1) | SG44652A1 (en) |
WO (1) | WO1993009222A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6893838B1 (en) | 1998-04-07 | 2005-05-17 | Genetics Institute Llc | DADD, death activator death domain protein |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6048729A (en) * | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US7094400B1 (en) * | 1987-05-01 | 2006-08-22 | Shire Human Genetic Therapies, Inc. | Transkaryotic implantation |
US5538722A (en) * | 1989-06-13 | 1996-07-23 | Stanford University | Isolation, growth, differentiation and genetic engineering of human muscle cells |
AU635844B2 (en) * | 1989-11-06 | 1993-04-01 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
ATE264916T1 (en) | 1989-12-22 | 2004-05-15 | Applied Research Systems | DNA CONSTRUCTS TO ACTIVATE AND ALTER THE EXPRESSION OF ENDOGENE GENES |
US6692737B1 (en) | 1991-11-05 | 2004-02-17 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
PT101031B (en) * | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY |
US6063630A (en) | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
FR2686899B1 (en) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US6670178B1 (en) | 1992-07-10 | 2003-12-30 | Transkaryotic Therapies, Inc. | In Vivo production and delivery of insulinotropin for gene therapy |
US6531124B1 (en) | 1992-07-10 | 2003-03-11 | Transkaryotic Therapies, Inc. | In vivo production and delivery of insulinotropin for gene therapy |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
AU678234B2 (en) | 1993-04-21 | 1997-05-22 | University Of Edinburgh, The | Expression of heterologous genes according to a targeted expression profile |
SE9402642D0 (en) * | 1994-08-05 | 1994-08-05 | Maria Anvret | Gene Therapy |
US6419920B1 (en) | 1995-10-25 | 2002-07-16 | Trans Karyotic Therapies, Inc. | Hybrid matrix implants and explants |
US5965125A (en) * | 1995-10-25 | 1999-10-12 | Transkaryotic Therapies, Inc. | Hybrid matrix implants and explants |
US5869041A (en) * | 1996-01-12 | 1999-02-09 | The Miriam Hospital | Delivery of bioactive compounds to an organism |
CA2243718A1 (en) * | 1996-02-06 | 1997-08-14 | Eli Lilly And Company | Diabetes therapy |
US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
KR20050084473A (en) | 1996-09-13 | 2005-08-26 | 트랜스케리오틱 쎄러피스, 인코포레이티드 | THERAPY FOR α-GALACTOSIDASE A DEFICIENCY |
US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
WO1998014592A2 (en) | 1996-10-01 | 1998-04-09 | Geron Corporation | Telomerase reverse transcriptase |
US5952226A (en) * | 1996-11-05 | 1999-09-14 | Modex Therapeutiques | Hypoxia responsive EPO producing cells |
CZ293355B6 (en) | 1997-03-14 | 2004-04-14 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and appropriate vectors for accomplishing the same |
US6172211B1 (en) | 1997-07-11 | 2001-01-09 | Boehringer Ingelheim International Gmbh | Nucleic acid encoding tag7 polypeptide |
US6548296B1 (en) | 1997-07-23 | 2003-04-15 | Roche Diagnostics Gmbh | Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof |
BRPI9811031B8 (en) * | 1997-07-23 | 2021-07-06 | Roche Diagnostics Gmbh | process for preparing a human epo producing cell, process for preparing human epo, constructing DNA for activating endogenous epo gene as well as plasmid. |
PT1000154E (en) | 1997-07-23 | 2007-03-30 | Roche Diagnostics Gmbh | Identification of human cell lines for the production of human proteins by endogenous gene activation |
EP1000154B1 (en) * | 1997-07-23 | 2007-02-21 | Roche Diagnostics GmbH | Identification of human cell lines for the production of human proteins by endogenous gene activation |
US6391633B1 (en) | 1997-07-23 | 2002-05-21 | Roche Diagnostics Gmbh | Production of erythropoietin by endogenous gene activation |
US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
US7316923B1 (en) | 1997-09-26 | 2008-01-08 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
US6897066B1 (en) | 1997-09-26 | 2005-05-24 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
ZA989497B (en) † | 1997-10-20 | 2000-04-19 | Roche Diagnostics Gmbh | Positive-negative selection in homologous recombination. |
AU744086B2 (en) | 1997-12-03 | 2002-02-14 | Roche Diagnostics Gmbh | Erythropoietin with high specific activity |
US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
US6426191B1 (en) | 1998-04-03 | 2002-07-30 | Hyseq, Inc. | Assays involving an IL-1 receptor antagonist |
US6541623B1 (en) | 1998-04-03 | 2003-04-01 | Hyseq, Inc. | Interleukin—1 receptor antagonist and uses thereof |
US6294655B1 (en) | 1998-04-03 | 2001-09-25 | Hyseq, Inc. | Anti-interleukin-1 receptor antagonist antibodies and uses thereof |
WO1999055866A1 (en) * | 1998-04-24 | 1999-11-04 | Transkaryotic Therapies, Inc. | Delivery of therapeutic proteins via implantation of genetically modified cells in the omentum |
US6537806B1 (en) * | 1998-06-02 | 2003-03-25 | University Of Washington | Compositions and methods for treating diabetes |
DK1100576T3 (en) * | 1998-06-26 | 2007-12-03 | Genetronics Inc | Synergism of photodynamic and electroperative effect on cell vitality as novel cytotoxic agent |
CA2337129A1 (en) | 1998-07-13 | 2000-01-20 | Genetronics, Inc. | Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications |
US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
CA2337652C (en) | 1998-07-13 | 2013-03-26 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6678556B1 (en) * | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
CA2351671A1 (en) * | 1998-11-24 | 2000-06-08 | Regents Of The University Of Minnesota | Transgenic circulating endothelial cells |
DE19857609A1 (en) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Use of erythropoietin for the treatment of human cerebral ischemia |
BR0010097A (en) | 1999-04-28 | 2002-02-13 | Genetics Inst | Isolated polynucleotide; host cell; process for the production of a protein encoded by the polynucleotide; protein; composition; and; antibody |
EP2067788B1 (en) | 1999-05-18 | 2015-07-22 | Dyax Corp. | Fab fragment libraries and methods for their use |
JP4723144B2 (en) | 1999-09-29 | 2011-07-13 | ザ ジェネラル ホスピタル コーポレイション | Polypeptide derivative of parathyroid hormone (PTH) |
IL149679A0 (en) * | 1999-11-19 | 2002-11-10 | Transkaryotic Therapies Inc | Nucleic acid construct and methods utilizing the same |
US8168178B2 (en) | 1999-11-30 | 2012-05-01 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
US6951839B1 (en) | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
WO2001042442A2 (en) | 1999-12-10 | 2001-06-14 | Cytos Biotechnology Ag | Activation of endogenous genes by genomic introduction of a replicon |
TW201006846A (en) | 2000-03-07 | 2010-02-16 | Senomyx Inc | T1R taste receptor and genes encidung same |
EP1728862A1 (en) | 2000-03-16 | 2006-12-06 | Genetica, Inc. | Methods and compositions for RNA interference |
US20030084471A1 (en) | 2000-03-16 | 2003-05-01 | David Beach | Methods and compositions for RNA interference |
EP1832599A3 (en) * | 2000-04-12 | 2007-11-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6686188B2 (en) * | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
US6656700B2 (en) * | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
KR100407792B1 (en) * | 2000-08-02 | 2003-12-01 | 한국생명공학연구원 | Preparation method of recombinant protein by use of human glucagon-derived peptide analogue as a fusion expression partner |
WO2002022151A2 (en) | 2000-09-18 | 2002-03-21 | Osteometer Bio Tech A/S | Use of glp-1 and flp-2 peptides for treatment of bone disorders |
US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
US20070135345A1 (en) * | 2000-09-18 | 2007-06-14 | Henriksen Dennis B | Use of GLP-2 for the treatment or prevention, of bone-related disorders |
US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
US20020123474A1 (en) * | 2000-10-04 | 2002-09-05 | Shannon Mark E. | Human GTP-Rho binding protein2 |
EP1345628B1 (en) | 2000-12-20 | 2011-04-13 | F. Hoffmann-La Roche AG | Conjugates of erythropoietin (epo) with polyethylene glycol (peg) |
PA8536201A1 (en) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin |
TW201022287A (en) | 2001-01-03 | 2010-06-16 | Senomyx Inc | T1R taste receptors and genes encoding same |
ES2328796T3 (en) | 2001-03-14 | 2009-11-18 | Myriad Genetics, Inc. | TSG101-GAG INTERACTION AND USE OF THE SAME. |
US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
CA2446739A1 (en) * | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
CA2451317C (en) | 2001-06-26 | 2016-03-29 | Senomyx, Inc. | T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds |
US20040204669A1 (en) * | 2001-07-05 | 2004-10-14 | Hofmann Gunter A. | Apparatus for electroporation mediated delivery for drugs and genes |
WO2003006482A2 (en) | 2001-07-10 | 2003-01-23 | Senomyx, Inc. | Use of specific t2r taste receptors to identify compounds that block bitter taste |
CN1363654A (en) * | 2001-07-19 | 2002-08-14 | 上海华谊生物技术有限公司 | Genetically engineered bacteria and process for preparing insulinotropic hormone secretion peptide GLP-1 (7-36) |
ATE445838T1 (en) * | 2001-07-25 | 2009-10-15 | Raptor Pharmaceutical Inc | COMPOSITIONS AND METHODS FOR MODULATING TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER |
US6867189B2 (en) * | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
US6642003B2 (en) | 2001-08-02 | 2003-11-04 | Cedars-Sinai Medical Center | Human glucose-dependent insulin-secreting cell line |
US20040078837A1 (en) * | 2001-08-02 | 2004-04-22 | Shannon Mark E. | Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12 |
US20040143104A1 (en) * | 2001-08-08 | 2004-07-22 | Wadsworth Samuel C. | Methods of treating diabetes and other blood sugar disorders |
BR0214217A (en) * | 2001-11-16 | 2004-09-21 | Childrens Medical Center | Increased Organ Function |
AU2002364587A1 (en) * | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
DK1463751T3 (en) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albumin Fusion Proteins. |
CN1296485C (en) * | 2002-01-17 | 2007-01-24 | 英国龙沙生物医药股份有限公司 | Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium |
US7772459B2 (en) | 2002-02-20 | 2010-08-10 | Bellweather Farms | Transgenic production in saliva |
US7141240B2 (en) * | 2002-03-12 | 2006-11-28 | Cedars-Sinai Medical Center | Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1 |
BR122017016940B8 (en) | 2002-04-25 | 2021-07-27 | Transkaryotic Therapies Inc | method for preparing a pharmaceutical composition comprising alpha-galactosidase a |
US7374930B2 (en) * | 2002-05-21 | 2008-05-20 | Expression Genetics, Inc. | GLP-1 gene delivery for the treatment of type 2 diabetes |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
AU2003263552A1 (en) * | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US20050048041A1 (en) * | 2003-01-13 | 2005-03-03 | Rao Mahendra S. | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
JP2006517101A (en) * | 2003-01-13 | 2006-07-20 | エス. ラオ、マヘンドラ | Sustained expression of candidate molecules in proliferating stem and progenitor cells to deliver therapeutic products |
EP2561887B8 (en) | 2003-01-14 | 2016-12-21 | Dana-Farber Cancer Institute, Inc. | Cancer therapy sensitizer |
US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
EP1660859A4 (en) | 2003-08-06 | 2012-10-10 | Senomyx Inc | T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds |
PL1696947T3 (en) * | 2003-12-19 | 2014-08-29 | Hoffmann La Roche | Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases |
EP2329714A1 (en) | 2004-08-03 | 2011-06-08 | Biogen Idec MA Inc. | Influence of TAJ in the neuronal functions |
EP2338994B1 (en) | 2004-09-02 | 2014-03-19 | Yale University | Regulation of oncogenes by microRNAs |
EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
US8354384B2 (en) | 2005-06-23 | 2013-01-15 | Yale University | Anti-aging micrornas |
US20100040636A1 (en) | 2005-09-09 | 2010-02-18 | The Johns Hopkins University | Manipulation of Regulatory T Cell and Dc Function By Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists |
CA2611349C (en) | 2005-10-20 | 2017-01-03 | Senomyx, Inc. | Chimeric human sweet-umami and umami-sweet taste receptors |
CA2626852A1 (en) | 2005-11-03 | 2007-05-18 | Redpoint Bio Corporation | High throughput screening assay for the trpm5 ion channel |
DE102006004008A1 (en) | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered |
US8129334B2 (en) | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
TWI425917B (en) | 2006-04-21 | 2014-02-11 | Senomyx Inc | Comestible compositions comprising high potency savory flavorants, and processes for producing them |
JP2007325571A (en) * | 2006-06-09 | 2007-12-20 | Toto Ltd | Method for producing protein using recombinant mammalian cell |
WO2007150069A2 (en) | 2006-06-23 | 2007-12-27 | Myriad Genetics, Inc. | Dpyd gene variants and use thereof |
WO2008013861A2 (en) | 2006-07-27 | 2008-01-31 | Redpoint Bio Corporation | Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol |
EP2120998B1 (en) | 2006-11-28 | 2013-08-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
WO2008141176A1 (en) | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
EA200971050A1 (en) | 2007-05-11 | 2010-06-30 | Томас Джефферсон Юниверсити | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS |
EP2162529B1 (en) | 2007-06-08 | 2019-03-27 | Wake Forest University Health Sciences | Selective cell therapy for the treatment of renal failure |
US10590391B2 (en) * | 2007-06-08 | 2020-03-17 | Wake Forest University Health Sciences | Selective cell therapy for the treatment of renal failure |
US9580688B2 (en) * | 2007-06-08 | 2017-02-28 | Wake Forest University Health Sciences | Kidney structures and methods of forming the same |
EP2006388A1 (en) * | 2007-06-19 | 2008-12-24 | Helmholtz-Zentrum für Infektionsforschung GmbH | Nucleic acid constructs for deactivation and conditional mutagenesis of genes |
CL2008002054A1 (en) | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Method for the regeneration of a cation exchange chromatography column after elusion of monopeglated erythropoietin and method to obtain a monopeglated erythropoietin, incorporating the regeneration method of the cation exchange column. |
CL2008002053A1 (en) | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Method for the purification of a monopeglated erythropoietin (epompeg) which consists of providing a solution containing mono, poly and non-peglated erythropoietin and passing it through two steps of cation exchange chromatography and a method to produce epo mpeg that includes a purification method. |
WO2009010107A1 (en) | 2007-07-19 | 2009-01-22 | Hannelore Ehrenreich | Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis |
MX353986B (en) | 2007-08-01 | 2017-11-06 | Massachusetts Gen Hospital | Screening methods using g-protein coupled receptors and related compositions. |
WO2009022656A1 (en) * | 2007-08-10 | 2009-02-19 | Toto Ltd. | Recombinant mammalian cells, method of producing recombinant mammalian cells and method of producing target protein |
AU2008289485B2 (en) | 2007-08-21 | 2014-08-14 | Senomyx, Inc. | Human T2R bitterness receptors and uses thereof |
US20090176729A1 (en) * | 2007-12-14 | 2009-07-09 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
CN105274072A (en) | 2008-01-18 | 2016-01-27 | 生物马林药物股份有限公司 | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
CN102232085A (en) | 2008-09-26 | 2011-11-02 | Ambrx公司 | Modified animal erythropoietin polypeptides and their uses |
WO2010037224A1 (en) | 2008-10-03 | 2010-04-08 | St. Michael's Hospital | Method for preventing and treating cardiovascular diseases with brca1 |
CN103937737B (en) * | 2008-11-12 | 2023-05-23 | 因瑞金公司 | Isolated kidney cells and uses thereof |
US20100178641A1 (en) * | 2009-01-12 | 2010-07-15 | Franklin David Damon | Apparel fastening learning apparatus |
US8211655B2 (en) | 2009-02-12 | 2012-07-03 | Discoverx Corporation | Wild-type receptor assays |
WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
KR20120117728A (en) | 2009-09-23 | 2012-10-24 | 바이오제너릭스 에이지 | Process for the purification of recombinant human erythropoietin(epo), epo thus purified and pharmaceutical compositions comprising same |
EP2569003B1 (en) | 2010-05-13 | 2017-10-25 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
AR082319A1 (en) | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | PRODUCTION OF A HIGHLY ACTIVE PHOSPHORILED HUMAN N-ACETILGALACTOSAMINE-6-SULPHATASE AND ITS USES |
RU2566267C2 (en) | 2010-09-14 | 2015-10-20 | Ф. Хоффманн-Ля Рош Аг | Method of purifying pegylated erythropoietin |
CA3065694A1 (en) | 2010-11-10 | 2012-05-18 | Inregen | Methods of forming injectable formulations for providing regenerative effects to an organ such as a kidney |
AU2011336467A1 (en) | 2010-12-01 | 2013-07-04 | Spinal Modulation, Inc. | Agent delivery systems for selective neuromodulation |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
WO2013006842A2 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
WO2013020044A1 (en) | 2011-08-03 | 2013-02-07 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center | Treatment of fibrosis using microrna-19b |
EP2869842A1 (en) | 2012-07-06 | 2015-05-13 | Novartis AG | Immunogenic compositions and uses thereof |
WO2014138921A1 (en) | 2013-03-15 | 2014-09-18 | Apotex Inc. | Enhanced liquid formulation stability of erythropoietin alpha through purification processing |
US10196601B2 (en) | 2013-08-20 | 2019-02-05 | Lek Pharmaceuticals D.D. | Cell culture medium and process for controlling α-amidation and/or C-terminal amino acid cleavage of polypeptides |
EP3194581A4 (en) | 2014-09-15 | 2018-04-25 | Children's Medical Center Corporation | Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation |
MA40871A (en) | 2014-10-29 | 2017-09-05 | Novartis Ag | DIRECT EXPRESSION OF ANTIBODIES |
WO2018011381A1 (en) | 2016-07-15 | 2018-01-18 | F. Hoffmann-La Roche Ag | Method for purifying pegylated erythropoietin |
US11123372B2 (en) | 2016-07-29 | 2021-09-21 | Prokidney | Bioactive renal cells for the treatment of chronic kidney disease |
CN111801120A (en) | 2017-12-29 | 2020-10-20 | 豪夫迈·罗氏有限公司 | Methods for providing pegylated protein compositions |
JP7137625B2 (en) | 2017-12-29 | 2022-09-14 | エフ.ホフマン-ラ ロシュ アーゲー | Methods for providing PEGylated protein compositions |
HRP20220388T1 (en) | 2017-12-29 | 2022-05-27 | F. Hoffmann - La Roche Ag | Process for providing pegylated protein composition |
KR20220148184A (en) * | 2020-03-04 | 2022-11-04 | 가부시키가이샤 메토세라 | Fibroblasts with enhanced erythropoietin-producing ability |
WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4396601A (en) * | 1980-03-26 | 1983-08-02 | The Regents Of The University Of Calif. | Gene transfer in intact mammals |
US4497796A (en) * | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
EP0038765B1 (en) * | 1980-04-22 | 1987-09-02 | Institut Pasteur | Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US4680174A (en) * | 1984-05-24 | 1987-07-14 | Damon Biotech, Inc. | Induction of immune response by immunization with encapsulated antigen-producing cells |
CA1215922A (en) * | 1984-05-25 | 1986-12-30 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
AU580145B2 (en) * | 1985-02-13 | 1989-01-05 | Scios Nova Inc. | Human metallothionein-ii promoter in mammalian expression system |
DE3681787D1 (en) * | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | EXPRESSION OF FOREIGN GENETIC MATERIAL IN EPITHELIC CELLS. |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
DE3789678T2 (en) * | 1986-02-27 | 1994-08-11 | Snow Brand Milk Products Co Ltd | Production of erythropoietin-producing cells and method for producing erythropoietin using these cells. |
US5118666A (en) * | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
DK173067B1 (en) * | 1986-06-27 | 1999-12-13 | Univ Washington | Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines |
GB8615942D0 (en) * | 1986-06-30 | 1986-08-06 | Animal & Food Research Council | Peptide production |
US5219740A (en) * | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5175255A (en) * | 1987-03-23 | 1992-12-29 | Amgen Inc. | Methods for purification of platelet-derived growth factor |
US6048729A (en) * | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
EP0289034B1 (en) * | 1987-05-01 | 1996-11-27 | The General Hospital Corporation | Transkaryotic implantation |
US5166059A (en) * | 1987-06-16 | 1992-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy using gene fusions for genetic or acquired disorders |
US5048477A (en) * | 1987-07-06 | 1991-09-17 | Komatsu Zenoah Kabushiki Kaisha | Fuel supply system for an engine |
GB8718779D0 (en) * | 1987-08-07 | 1987-09-16 | Grosveld F G | Dna sequence & expression vector |
WO1989002468A1 (en) * | 1987-09-11 | 1989-03-23 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
DE3851153T2 (en) * | 1987-12-11 | 1995-01-05 | Whitehead Biomedical Inst | GENETIC MODIFICATION OF ENDOTHELIAL CELLS. |
US4890286A (en) * | 1987-12-11 | 1989-12-26 | Sanyo Electric Co., Ltd. | Method and apparatus for decoding error correcting code |
DE3802640A1 (en) * | 1988-01-29 | 1989-08-03 | Roehm Gmbh | HAIR-RESERVED AASIS PROCEDURE |
WO1989007136A2 (en) * | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
EP0456640A1 (en) * | 1988-12-13 | 1991-11-21 | UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Genetically engineered endothelial cells and use thereof |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
FR2646438B1 (en) * | 1989-03-20 | 2007-11-02 | Pasteur Institut | A METHOD FOR SPECIFIC REPLACEMENT OF A COPY OF A GENE PRESENT IN THE RECEIVER GENOME BY INTEGRATION OF A GENE DIFFERENT FROM THAT OR INTEGRATION |
GB8907700D0 (en) * | 1989-04-05 | 1989-05-17 | Fine Organics Ltd | Preparation of substituted ethenes |
GB8909218D0 (en) * | 1989-04-22 | 1989-06-07 | Medical Res Council | Improvements in or relating to enhancers |
WO1990015863A1 (en) * | 1989-06-13 | 1990-12-27 | The Board Of Directors Of The Leland Stanford Junior University | Isolation growth and differentiation of human muscle cells |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5464764A (en) * | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
AU635844B2 (en) * | 1989-11-06 | 1993-04-01 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
ATE264916T1 (en) * | 1989-12-22 | 2004-05-15 | Applied Research Systems | DNA CONSTRUCTS TO ACTIVATE AND ALTER THE EXPRESSION OF ENDOGENE GENES |
US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
WO1991013151A1 (en) * | 1990-02-22 | 1991-09-05 | Biogen, Inc. | Improved expression of polypeptides |
IT1241123B (en) * | 1990-04-19 | 1993-12-29 | Consiglio Nazionale Ricerche | HUMAN CELLS FOR THE HIGH EXPRESSION OF GENES INSERTED IN DNA EPISOMIAL RECOMBINANTS, THEIR PREPARATION AND THEIR USE |
CA2084774A1 (en) * | 1990-06-12 | 1991-12-13 | Allan Bradley | Method for homologous recombination in animal and plant cells |
WO1992003917A1 (en) * | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
JP3418982B2 (en) * | 1990-10-31 | 2003-06-23 | ソマティクス セラピー コーポレイション | Genetic degeneration of endothelial cells |
EP0557459B1 (en) * | 1990-11-13 | 1997-10-22 | Immunex Corporation | Bifunctional selectable fusion genes |
AU9179591A (en) * | 1990-12-26 | 1992-08-17 | Howard Hughes Medical Center | Modified hepatocytes and uses therefor |
WO1992015676A1 (en) * | 1991-03-08 | 1992-09-17 | The Salk Institute For Biological Studies | Somatic cell gene therapy |
ATE272121T1 (en) * | 1991-05-06 | 2004-08-15 | Cell Genesys Inc | GENE MANIPULATION AND EXPRESSION USING GENOMIC ELEMENTS |
WO1992020808A1 (en) * | 1991-05-15 | 1992-11-26 | Cell Genesys, Inc. | Genomic modifications with homologous dna targeting |
AU2515992A (en) * | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US6054288A (en) * | 1991-11-05 | 2000-04-25 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
US6063630A (en) * | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
PT101031B (en) * | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | PROCESS FOR THE SUPPLY OF PROTEINS BY GENETIC THERAPY |
US6531124B1 (en) * | 1992-07-10 | 2003-03-11 | Transkaryotic Therapies, Inc. | In vivo production and delivery of insulinotropin for gene therapy |
US6670178B1 (en) * | 1992-07-10 | 2003-12-30 | Transkaryotic Therapies, Inc. | In Vivo production and delivery of insulinotropin for gene therapy |
KR960037062A (en) * | 1996-08-02 | 1996-11-19 | 오동덕 | Manufacturing method of therapeutic agent for purulent skin disease |
-
1992
- 1992-11-04 PT PT101031A patent/PT101031B/en not_active IP Right Cessation
- 1992-11-04 NZ NZ245015A patent/NZ245015A/en not_active IP Right Cessation
- 1992-11-05 EP EP92924367A patent/EP0649464B1/en not_active Revoked
- 1992-11-05 WO PCT/US1992/009627 patent/WO1993009222A2/en not_active Application Discontinuation
- 1992-11-05 DE DE69221168T patent/DE69221168T2/en not_active Revoked
- 1992-11-05 EP EP96202037A patent/EP0750044B1/en not_active Expired - Lifetime
- 1992-11-05 IL IL103649A patent/IL103649A0/en not_active IP Right Cessation
- 1992-11-05 MX MX9206376A patent/MX9206376A/en active IP Right Grant
- 1992-11-05 DK DK96202037T patent/DK0750044T3/en active
- 1992-11-05 MY MYPI92002007A patent/MY119132A/en unknown
- 1992-11-05 DE DE69232728T patent/DE69232728T2/en not_active Expired - Fee Related
- 1992-11-05 DK DK92924367.3T patent/DK0649464T3/en active
- 1992-11-05 AU AU30698/92A patent/AU669499B2/en not_active Ceased
- 1992-11-05 ES ES96202037T patent/ES2181841T3/en not_active Expired - Lifetime
- 1992-11-05 EP EP01204619A patent/EP1221477A3/en not_active Withdrawn
- 1992-11-05 SG SG1996005101A patent/SG44652A1/en unknown
- 1992-11-05 CA CA002122991A patent/CA2122991A1/en not_active Abandoned
- 1992-11-05 JP JP50876793A patent/JP3564126B2/en not_active Expired - Fee Related
- 1992-11-05 AT AT92924367T patent/ATE155810T1/en not_active IP Right Cessation
- 1992-11-05 AT AT96202037T patent/ATE221917T1/en not_active IP Right Cessation
- 1992-11-05 ES ES92924367T patent/ES2106891T3/en not_active Expired - Lifetime
-
1994
- 1994-05-04 KR KR10-1994-0701527A patent/KR100339316B1/ko not_active IP Right Cessation
- 1994-11-04 US US08/334,455 patent/US5994127A/en not_active Expired - Lifetime
-
1995
- 1995-05-22 US US08/446,909 patent/US6048524A/en not_active Expired - Lifetime
- 1995-05-22 US US08/446,911 patent/US6048724A/en not_active Expired - Lifetime
-
1997
- 1997-10-15 GR GR970402700T patent/GR3025054T3/en unknown
-
1998
- 1998-12-24 HK HK98115412A patent/HK1014033A1/en not_active IP Right Cessation
-
1999
- 1999-06-08 US US09/328,130 patent/US6846676B2/en not_active Expired - Fee Related
- 1999-10-19 US US09/420,861 patent/US6355241B1/en not_active Expired - Lifetime
-
2002
- 2002-12-11 JP JP2002359926A patent/JP3733110B2/en not_active Expired - Fee Related
-
2004
- 2004-07-07 US US10/885,899 patent/US7410799B2/en not_active Expired - Lifetime
- 2004-07-22 JP JP2004214021A patent/JP2005046147A/en active Pending
-
2008
- 2008-06-24 US US12/145,324 patent/US20100143314A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9309222A3 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6893838B1 (en) | 1998-04-07 | 2005-05-17 | Genetics Institute Llc | DADD, death activator death domain protein |
US7576178B2 (en) | 1998-04-07 | 2009-08-18 | Genetics Institute, Llc | DADD, death activator death domain protein |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100339316B1 (en) | ||
MY140230A (en) | Activating expression of an amplifying endogenous gene by homologous recombination | |
JP4562915B2 (en) | Overexpression of the desired protein in eukaryotic cells mediated by overexpression of cyclin D1 | |
MX9605542A (en) | Dna construct for effecting homologous recombination and uses thereof. | |
NL930127I1 (en) | Formation of a multi-active granulocyte colony stimulating factor | |
IE883244L (en) | Production of chimeric antibodies by homologous recombination | |
WO1999064565A3 (en) | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells | |
CN103923942A (en) | Transposable element carrier expressing pig telomerase reverse transcriptase, building method thereof and application in building pig immortalization cell line | |
CN104342454A (en) | Expression vector for producing protein derived from foreign gene in large quantity using animal cells, and use thereof | |
JO1694B1 (en) | New chemical products | |
JP6469371B2 (en) | A method for expressing a plurality of foreign genes in an embryoid body composed of induced pluripotent stem cells (iPS cells) | |
Li et al. | Retrovectors packaged in CHO cells to generate GLP-1-Fc stable expression CHO cell lines | |
Lampela et al. | Efficient transfection of novel bovine papillomavirus 1 expression plasmids | |
CN104995299A (en) | Expression cassette | |
Monaco | Optimizing gene expression in mammalian cells | |
CN109097357A (en) | A kind of artificial synthesized MAR consensus sequence, expression vector, expression system and its application | |
Moreau-Toussaint et al. | Efficient mRNA Delivery in difficult-to-transfect cells with jetMESSENGER® Transfection Reagent | |
Le Blay et al. | Efficient transient gene expression in neurosphere with jetMESSENGER™ mRNA Transfection Reagent | |
Pavlin et al. | Optimization of electrotransfer parameters for siRNA delivery into primary human myoblasts | |
Girard et al. | Scalable, Serum-Free, High Efficiency Transfection of CHO Cells Using an Economical DNA Transfer Vehicle | |
CN103509754A (en) | On-HIV-1 LTR cis-element mutant eukaryotic cell system, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19940531 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE |
|
17Q | First examination report despatched |
Effective date: 19950927 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE |
|
REF | Corresponds to: |
Ref document number: 155810 Country of ref document: AT Date of ref document: 19970815 Kind code of ref document: T |
|
XX | Miscellaneous (additional remarks) |
Free format text: TEILANMELDUNG 96202037.6 EINGEREICHT AM 18/07/96. |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69221168 Country of ref document: DE Date of ref document: 19970904 |
|
ITF | It: translation for a ep patent filed |
Owner name: ING. BETTELLO LUIGI |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2106891 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3025054 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
26 | Opposition filed |
Opponent name: BOEHRINGER MANNHEIM GMBH PATENTABTEILUNG Effective date: 19980422 Opponent name: CELL GENESYS, INC. Effective date: 19980423 Opponent name: APPLIED RESEARCH SYSTEMS ARS HOLDING NV Effective date: 19980423 Opponent name: INSTITUT PASTEUR Effective date: 19980423 Opponent name: GENETIC THERAPY, INC Effective date: 19980423 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: BOEHRINGER MANNHEIM GMBH PATENTABTEILUNG Opponent name: CELL GENESYS, INC. Opponent name: APPLIED RESEARCH SYSTEMS ARS HOLDING NV Opponent name: INSTITUT PASTEUR Opponent name: GENETIC THERAPY, INC |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
R26 | Opposition filed (corrected) |
Opponent name: GENETIC THERAPY, INC * 980423 INSTITUT PASTEUR * 9 Effective date: 19980423 |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: ROCHE DIAGNOSTICS GMBH Opponent name: CELL GENESYS, INC. Opponent name: APPLIED RESEARCH SYSTEMS ARS HOLDING NV Opponent name: INSTITUT PASTEUR Opponent name: GENETIC THERAPY, INC |
|
PLBF | Reply of patent proprietor to notice(s) of opposition |
Free format text: ORIGINAL CODE: EPIDOS OBSO |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
R26 | Opposition filed (corrected) |
Opponent name: GENETIC THERAPY, INC * 19980423 INSTITUT PASTEUR * Effective date: 19980423 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: ROCHE DIAGNOSTICS GMBH Opponent name: CELL GENESYS, INC. Opponent name: APPLIED RESEARCH SYSTEMS ARS HOLDING NV Opponent name: INSTITUT PASTEUR Opponent name: GENETIC THERAPY, INC |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
R26 | Opposition filed (corrected) |
Opponent name: GENETIC THERAPY, INC * 19980423 INSTITUT PASTEUR * Effective date: 19980423 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: ROCHE DIAGNOSTICS GMBH Opponent name: CELL GENESYS, INC. Opponent name: APPLIED RESEARCH SYSTEMS ARS HOLDING NV Opponent name: INSTITUT PASTEUR Opponent name: GENETIC THERAPY, INC |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
R26 | Opposition filed (corrected) |
Opponent name: GENETIC THERAPY, INC * 19980423 INSTITUT PASTEUR * Effective date: 19980423 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: ROCHE DIAGNOSTICS GMBH Opponent name: CELL GENESYS, INC. Opponent name: APPLIED RESEARCH SYSTEMS ARS HOLDING NV Opponent name: INSTITUT PASTEUR Opponent name: GENETIC THERAPY, INC |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
RDAH | Patent revoked |
Free format text: ORIGINAL CODE: EPIDOS REVO |
|
APAC | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPO |
|
APAC | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPO |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
R26 | Opposition filed (corrected) |
Opponent name: GENETIC THERAPY, INC * 19980423 INSTITUT PASTEUR * Effective date: 19980423 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: ROCHE DIAGNOSTICS GMBH Opponent name: CELL GENESYS, INC. Opponent name: APPLIED RESEARCH SYSTEMS ARS HOLDING NV Opponent name: INSTITUT PASTEUR Opponent name: GENETIC THERAPY, INC |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20031029 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20041103 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20041105 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20041109 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20041111 Year of fee payment: 13 Ref country code: AT Payment date: 20041111 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20041116 Year of fee payment: 13 Ref country code: LU Payment date: 20041116 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20041117 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20041214 Year of fee payment: 13 |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
APAA | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOS REFN |
|
APBU | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9O |
|
RDAG | Patent revoked |
Free format text: ORIGINAL CODE: 0009271 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT REVOKED |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20050215 Year of fee payment: 13 |
|
R26 | Opposition filed (corrected) |
Opponent name: ROCHE DIAGNOSTICS GMBH Effective date: 19980422 Opponent name: CELL GENESYS, INC. Effective date: 19980423 Opponent name: APPLIED RESEARCH SYSTEMSARS HOLDING NV Effective date: 19980423 Opponent name: INSTITUT PASTEUR Effective date: 19980423 Opponent name: GENETIC THERAPY, INC Effective date: 19980423 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
27W | Patent revoked |
Effective date: 20041116 |
|
GBPR | Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state |
Free format text: 20041116 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: ROCHE DIAGNOSTICS GMBH Opponent name: CELL GENESYS, INC. Opponent name: APPLIED RESEARCH SYSTEMS ARS HOLDING NV Opponent name: INSTITUT PASTEUR Opponent name: GENETIC THERAPY, INC |
|
NLR2 | Nl: decision of opposition |
Effective date: 20041116 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: ECNC |
|
APAH | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNO |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20051012 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20051026 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20061130 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20070531 Year of fee payment: 15 |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |